Nls pharmaceutics announces receipt of staff delisting determination from nasdaq; intends to request hearing

ZÜrich, switzerland / accesswire / october 5, 2022 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that on september 29, 2022, it received a determination letter (the "letter") from the staff (the "staff") of the listing qualifications department of the nasdaq stock market llc ("nasdaq") notifying the company of the staff's determination that, unless the company timely requests a hearing before a nasdaq hearings panel (the "panel"), the company's securities would be subject to delisting from the nasdaq capital market due to the company's failure to regain compliance with the minimum stockholders' equity requirement for continued listing on the nasdaq capital market, as set forth in nasdaq listing rule 5550(b)(1).
NLSP Ratings Summary
NLSP Quant Ranking